Seven Keys to Treating Prostate Cancer
Author:
Jacek L. Mostwin,
M.D.,
D. Phil. (Oxon)
Medical Editor of The Johns Hopkins Prostate Bulletin
Dr. Mostwin, one of the leading urological surgeons at Johns
Hopkins' world-renowned James Buchanan Brady Urological Institute, maintains a busy medical practice focusing on prostate
cancer. He has performed more than 2,800 radical prostatectomies in his career. Among his major research interests are urinary
continence issues and bladder function. Most of Dr.
Mostwin's scientific publications have dealt with lower
urinary tract problems.
MEDICAL ADVISORY BOARD
Johns Hopkins
Prostate Bulletin:
H. Ballentine Carter, M.D.
is a Professor of Urology and Oncology at The Johns Hopkins Medical School and a practicing surgeon. He is a recognized expert in the diagnosis, staging, and treatment of prostate cancer. Dr. Carter pioneered the concept of PSA (Prostate Specific Antigen) changes (PSA velocity) as a marker of prostate cancer presence, and the use of free PSA to predict the behavior of prostate cancer.
Dr. Carter is working closely with colleagues at the Baltimore Longitudinal of Study of Aging (National Institute of Aging) to track the incidence of prostate disease in men as they age. These longitudinal studies could help identify risk factors involved in the development of prostate disease.
The founding medical editor of The Johns Hopkins Prostate Bulletin, Dr. Carter now serves on its Medical Advisory Board. He is also currently a consulting editor to the journal Urology, and medical editor of The Johns Hopkins White Paper: Prostate Disorders. Dr. Carter is the primary author or co-author of more than six dozen major urological studies published in peer-reviewed journals, as well as the principal author or co-author of more than two dozen textbook articles on urology.
Alan W. Partin, M.D., Ph.D.
is a renowned surgeon, researcher, and teacher whose work has influenced urological advances. Dr. Partin, Professor and Director of the James Buchanan Brady Urological Institute at Johns Hopkins, has both a basic science and clinical interest in prognosis prediction for men with prostate cancer.
Over the years, Dr. Partin has focused his scientific attention on the development and testing of new and existing methods for predicting the aggressiveness of prostate cancers so that rational treatment decisions can be made by both patients and physicians.
The Partin tables, the diagnostic prostate cancer nomograms that Dr. Partin developed in 1993, now help prostate cancer patients the world over get an accurate prediction of their likelihood of being cured.
The Johns Hopkins James Buchanan Brady Urological Institute
is dedicated to providing state-of-the-art medical and surgical care in all aspects of adult urology. Now, you can benefit from the that remarkable heritage of medical expertise, innovation and careful attention to urological diagnosis and treatment, through the Johns Hopkins Prostate Publications.
JOHNS HOPKINS MEDICAL LETTER:
Health After 50
EDITORIAL BOARD OF ADVISORS
Medical Editor:
Simeon Margolis, M.D.,
Ph.D., Professor, Medicine
and Biological Chemistry
Martin D. Abeloff,
M.D.,
Director,
Sidney Kimmel Comprehensive
Cancer Center
Michele F. Bellantoni,
M.D.,
Associate Professor, Medicine;
Medical Director, Long Term Care,
Johns Hopkins Care Center
Susan B. Bressler
M.D.,
Professor, Medicine, Ophthalmology
H. Ballentine Carter,
M.D.,
Professor & Director,
Adult Urology
Barbara de Lateur,
M.D.
Professor,
Physical Medicine & Rehabilitation
John A. Flynn,
M.D.,
Associate Professor, Medicine;
Clinical Director,
Division of General Internal Medicine
H. Franklin Herlong,
M.D.,
Associate Professor, Medicine
Bruce Perler,
M.D.,
Professor, Surgery;
Director Division of Vascular Surgery
Peter Rabins,
M.D.,
Professor, Psychiatry;
Director, Division of
Geriatric & Neuropsychiatry
Edward E. Wallach,
M.D.,
Professor,
Gynecology & Obstetrics
James Weiss, M.D.,
Associate Dean;
Professor, Medicine,
Cardiology Division
|
